IDEXX Laboratories, Inc. $IDXX Stock Holdings Lifted by ProShare Advisors LLC

ProShare Advisors LLC increased its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 3.8% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 97,635 shares of the company’s stock after acquiring an additional 3,584 shares during the period. ProShare Advisors LLC owned approximately 0.12% of IDEXX Laboratories worth $50,984,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in IDXX. Arlington Trust Co LLC lifted its stake in shares of IDEXX Laboratories by 46.3% in the 2nd quarter. Arlington Trust Co LLC now owns 60 shares of the company’s stock valued at $32,000 after purchasing an additional 19 shares during the last quarter. Annis Gardner Whiting Capital Advisors LLC grew its holdings in shares of IDEXX Laboratories by 21.4% during the 1st quarter. Annis Gardner Whiting Capital Advisors LLC now owns 119 shares of the company’s stock worth $67,000 after purchasing an additional 21 shares during the period. Arlington Capital Management Inc. increased its position in shares of IDEXX Laboratories by 4.8% during the 1st quarter. Arlington Capital Management Inc. now owns 479 shares of the company’s stock worth $269,000 after purchasing an additional 22 shares during the last quarter. Valeo Financial Advisors LLC raised its holdings in IDEXX Laboratories by 6.4% in the 2nd quarter. Valeo Financial Advisors LLC now owns 383 shares of the company’s stock valued at $202,000 after buying an additional 23 shares during the period. Finally, Carnegie Investment Counsel raised its holdings in IDEXX Laboratories by 1.3% in the 1st quarter. Carnegie Investment Counsel now owns 2,000 shares of the company’s stock valued at $1,124,000 after buying an additional 25 shares during the period. Institutional investors and hedge funds own 87.84% of the company’s stock.

Wall Street Analysts Forecast Growth

IDXX has been the subject of a number of research analyst reports. UBS Group lowered their price objective on shares of IDEXX Laboratories from $670.00 to $627.00 and set a “neutral” rating for the company in a research report on Tuesday, October 27th. JPMorgan Chase & Co. cut their target price on IDEXX Laboratories from $775.00 to $750.00 and set an “overweight” rating on the stock in a research report on Friday, October 16th. The Goldman Sachs Group assumed coverage on IDEXX Laboratories in a research note on Friday, October 16th. They set a “buy” rating and a $740.00 price target on the stock. Wall Street Zen lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Finally, Barclays dropped their price objective on IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a research note on Tuesday, August 11th. Eight analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $721.67.

Insider Activity

In other news, Director Lawrence D. Kingsley sold 2,203 shares of the company’s stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the completion of the transaction, the director directly owned 9,568 shares of the company’s stock, valued at approximately $5,090,941.44. This represents a 18.72% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 0.79% of the company’s stock.

IDEXX Laboratories Price Performance

Shares of IDXX opened at $551.21 on Monday. The firm has a market capitalization of $43.42 billion, a price-to-earnings ratio of 38.76 and a beta of 1.55. The firm’s fifty day simple moving average is $534.27 and its 200-day simple moving average is $574.09. IDEXX Laboratories, Inc. has a twelve month low of $500.61 and a twelve month high of $769.98. The company has a current ratio of 1.17, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Monday, November 2nd. The company reported $3.96 EPS for the quarter, topping analysts’ consensus estimates of $3.73 by $0.23. The firm had revenue of $1.21 billion during the quarter, compared to the consensus estimate of $1.19 billion. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. Equities analysts forecast that IDEXX Laboratories, Inc. will post 14.81 EPS for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX’s companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.